Psoriasis Treatment Market to Grow at a CAGR of 8.36% During Forecast Period; Focus on Long-Term Management Using Targeted and Convenient Therapies to Fuel Market Growth

The global psoriasis treatment market size was valued at USD 29.26 billion in 2025. The market is projected to grow from USD 31.51 billion in 2026 to USD 59.89 billion by 2034, exhibiting a CAGR of 8.36% during the forecast period.

Fortune Business Insights™ presents this information in its report titled, “Psoriasis Treatment Market Size, Share & Industry Analysis, By Drug Class (TNF Inhibitors, Interleukin Inhibitors [IL-17, IL-23/p19, and IL-12/23 p40 Inhibitors], PDE4 Inhibitors, JAK Inhibitors, and Corticosteroids), By Indication (Plaque Psoriasis, Psoriatic Arthritis, Guttate Psoriasis, and Inverse Psoriasis), By Product Type (Biologics and Non-Biologics), By Route of Administration (Oral, Parenteral/Systemic, and Topical), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Specialty Pharmacies), and Regional Forecast, 2026-2034”.

Psoriasis, an autoimmune inflammatory disorder, is marked by excessive skin cell production that causes itchy, painful red lesions with plaque formation. Growth of the global market is attributed to a shift by patients and healthcare providers from short-term symptom control toward long-term management using targeted and convenient therapies. This growth is primarily driven by rising awareness of psoriasis as a systemic inflammatory disease and increasing demand for improved skin clearance.

New Sotyktu Approval to Strengthen Psoraitic Arthritis Portfolio

In March 2026, Bristol Myers Squibb obtained U.S. FDA approval for Sotyktu (deucravacitinib) to treat active psoriatic arthritis (PsA) in adults. Sotyktu is an oral, selective tyrosine kinase 2 (TYK2) inhibitor indicated for PsA.

Growing Patient Pool to Drive Market Growth

The expanding patient pool, especially moderate-to-severe cases unresponsive to topicals or phototherapy, is driving demand for advanced systemic treatments. Increased awareness is expanding dermatology and rheumatology care and uptake of targeted therapies, while biosimilars improve affordability and access in cost-sensitive markets is driving the psoriasis treatment market growth.

However, high costs linked to systemic therapies, limit adoption of treatment.

Key Players to Strengthen their Foothold in Market through Product Innovations and Wider Geographical Reach

The global market exhibits moderate consolidation, where competitive leadership comes from firms providing established biologics, biosimilars, systemic oral therapies, and advanced topicals. Prominent companies are reinforcing their market foothold through new product introductions, expanded indications, long-term clinical evidence, and wider geographical reach. Moreover, niche players are competing on the basis of distinct mechanisms of action, enhances dosing convenience, and dedicated therapies for hard-to-treat patient segments.

Notable Industry Development

• March 2026: Johnson & Johnson secured U.S. FDA approval for ICOTYDE (icotrokinra) for moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older.

List of the Companies Profiled in the Report

• AbbVie Inc. (U.S.)
• Novartis AG (Switzerland)
• Johnson & Johnson Services, Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• LEO Pharma A/S (Denmark)
• Amgen Inc. (U.S.)
• UCB S.A. (Belgium)
• Sun Pharmaceutical Industries Ltd.(India)
• Almirall, S.A (Spain)
• Arcutis Biotherapeutics, Inc. (U.S.)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/psoriasis-treatment-market-100600

Further Report Findings

• North America accounted for the largest psoriasis treatment market share. The region’s growth is supported by high diagnosis, strong access to dermatology care, and swift uptake of biologics, biosimilars, and oral systemic treatments.   
• Europe to grow at the second highest growth rate. Growth is driven by well-established reimbursement frameworks and robust clinical guidelines. Increased use of IL-17, IL-23, and advanced oral therapies is enhancing long-term management for moderate-to-severe patients.

Table of Segmentation